Drugs / PF-06817024
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02743871 | Apr 2016 → Mar 2021 | atopic eczema, chronic rhinosinusitis | Pfizer | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PF-06817024 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02743871 ↗ |
| Action | Inhibit | “potential to inhibit downstream type 2 inflammation” PMID 37772436 ↗ Oct 2023 |
| Modality | Monoclonal antibody | “PF-06817024 is a high affinity, humanized antibody that binds interleukin-33” PMID 37772436 ↗ Oct 2023 |
| Route | Intravenous | “Subjects will be given one dose of PF-06817024 intravenously” NCT02743871 ↗ |